Winton Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Winton Group’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,400	Closed	-$302K	–	1107
2025 Q4	$302K	Buy	+10,400	New	+$266K	0.01%	741

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Winton Group's ARQT Position: Q1 2026 in Review

Winton Group sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 10,400 shares — an estimated $302K sold.

Winton Group first reported a position in ARQT in Q4 2025 and held it in 1 quarter. The position peaked at $302K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

Winton Group reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
Winton Group sold 10,400 Arcutis Biotherapeutics shares in Q1 2026, an estimated $302K.
Winton Group first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 1 quarter.
Winton Group's Arcutis Biotherapeutics position peaked at $302K in Q4 2025.
270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.